


# DRUGS IN PARKINSONISM

## ILOS

Describe the pharmacological approach for treatment of Parkinsonism


Detail on the pharmacokinetic aspects and pharmacodynamic effects of drugs used to treat Parkinsonism



## DRUGS IN PA

A progressive disorder that occur mainly in the elderly

- Tremor at rest
- Muscle rigidity
- Hypokinesia
- Postural instability



# APPROACH FOR TREATMENT


Replacement of dopamine by levodopa

Drugs that mimic the effects of dopamine at D2 & D3-receptors

MAO-B inhibitors e.g. selegiline

Drugs that release dopamine e.g. amantadine

Muscarinic acetylcholine antagonists e.g. benztropine




# LEVODOPA

Combined with peripheral dopa decarboxylase inhibitors (carbidopa, benserazide)

Absorbed from the small intestine & crosses BBB by active transport,  $t_{1/2}=2h$

Effective against all types of parkinsonism except those associated with antipsychotic drug therapy.




# MOTOR FLUCTUATIONS

wearing-off effect

on-off effect

Dyskinesias




## ADRS

Orthostatic hypotension

Cardiac arrhythmias

CNS ADRs

vivid dreams, delusions,  
hallucinations, confusion and  
sleep disturbances



# CONTRAINDICATIONS


Nonselective MAO inhibitors  
(phenelzine, tranylcypromine)

Pyridoxine

Adrenomimetic amines

Cardiac arrhythmias or  
recent cardiac infarction

Proteins ingested with meals




# DOPAMINE RECEPTOR AGONISTS

Long duration of action ,less likely to cause dyskinesias than levodopa

As monotherapy, they are less effective than levodopa

Combined with levodopa in advanced stages →clinical improvement

+ ↓levodopa dosage needs






# CLASSIFICATION

ERGOT  
DERIVATIVES

bromocriptine, pergolide

SYNTHETICS

pramipexole, ropinirole



# BROMOCRIPTINE

ADRS


a partial D1-antagonist

Postural hypotension, nausea, somnolence Peak plasma levels are reached within 1–2 hours after an oral dose.

Confusion, hallucinations, delusions

Dyskinesias

Used for hyperprolactinemia




# CONTRAINDICATIONS

History of psychotic illness

Recent myocardial infarction

Active peptic ulceration

Best avoided in patients with peripheral vascular disease




# PRAMIPEXOLE

Has preferential affinity for the D3 family of receptors

Rapidly absorbed, reaching peak plasma concentrations in approximately 2 hours, excreted largely unchanged in the urine

Renal insufficiency may necessitate dosage adjustment



# AMANTADINE

## ADRS

Nausea, dizziness, insomnia, confusion, hallucinations  
adjunct to levodopa therapy

Ankle edema, and livedo reticularis

Affects dopamine release and reuptake,

## CONTRAINDICATIONS

D<sub>2</sub> receptors

Anticholinergics

50-75% in 24h, most of the drug being excreted unchanged  
in the urine



# SELEGILINE


An irreversible inhibitor of MAO-B

Blockade of dopamine metabolism makes more dopamine available for stimulation of its receptors.

As monotherapy, may be effective in the newly diagnosed patient


In later-stage, it is used in conjunction with levodopa-carbidopa → reduces levodopa dosage requirements

Minimize or delay the onset of dyskinesias and motor fluctuations that accompany treatment with levodopa




# SELEGILINE, RASAGILINE

It slows the progression of the disease by ↓ the formation of toxic **free radicals** produced during the metabolism of dopamine.



Metabolized to desmethylselegiline, Which is **antiapoptotic**



# SELEGILINE

## ADRS


At higher doses may inhibit MAO-A

May cause insomnia when taken later during the day

May ↑ the adverse effects of levodopa

## CONTRAINDICATIONS

Should not be co administered with TCA, meperidine or SSRIs





# ANTICHOLINERGIC DRUGS

Efficacy is due to blockade of muscarinic receptors in the striatum

*Modest efficacy, used during the early stages of the disease or as an adjunct to levodopa*

Anticholinergics can provide benefit in drug-induced parkinsonism


e.g. **Benztropine, Trihexyphenidyl.**



# ADRS

## CLINICAL CONTROVERSY

Some clinicians are concerned with possible long-term risks (motor fluctuations) of L-dopa and will delay or avoid its use even though it is more effective than other medications currently available. Others believe that motor fluctuations are a consequence of disease severity and progression rather than due to L-dopa itself. Individualized considerations of a patient's disability should guide all interventions for IPD.



# Case

M. S. is a 60-year old architect who designs buildings. His drawings are very detailed and they must be drawn to a specific scale. During the past month he has developed a slight tremor in his right hand that causes some embarrassment but does not interfere with function. He has, however, noticed that his writing and drawing have gotten much smaller, causing problems with his work. His primary care physician has referred him to a neurologist for evaluation. On examination, the neurologist notes some motor rigidity in the right arm. He also observes a slight slowing in the patient's walk and a reduction in the swing of his arms as he walks. What is the diagnosis, and how should the patient be treated?



## Quiz 1?

- **Great caution must be exercised in the use of this drug in parkinsonian patients who have prostatic hypertrophy :-**
  - **(A) Benztropine**
  - **(B) Carbidopa**
  - **(C) Levodopa**
  - **(D) Bromocriptine**
  - **(E) Selegiline**



## Quiz 2?

- A drug that is used in the treatment of parkinsonism and will also attenuate reversible extrapyramidal side effects of neuroleptics is
  - (A) Amantadine
  - (B) Levodopa
  - (C) Pergolide
  - (D) Selegiline
  - (E) Trihexyphenidyl

